Self-Administered Etripamil Cuts ED Visits for PSVT
Participants were randomly assigned to receive 70 mg of intranasal etripamil (n = 206) or placebo (n = 134). In the RAPID study, a second dose of etripamil was permitted 10 minutes after the first if symptoms persisted.
Electrocardiogram recordings were used to confirm the occurrence of PSVT episodes and their termination following study drug administration.
The study outcome was an emergency care visit within 24 hours of treatment. TAKEAWAY: Vagal maneuvers were attempted by 370 patients, but these maneuvers terminated PSVT in only 4.6% of cases without clinician assistance.
PSVT was terminated within 30 minutes in 57.8% of patients who received etripamil vs 32.1% of those who received placebo ( P < .001).
< .001). ED visits occurred in 13.6% of the etripamil group vs 22.4% of the placebo group, reflecting an 8.8% absolute risk reduction and a 39% relative risk reduction (relative risk, 0.61; P = .04).
= .04). Fewer etripamil recipients required additional medical intervention than placebo recipients (14.6% vs 25.4%; P = .01). No serious adverse events were noted with etripamil; the most common events were localized to the nasal administration site. IN PRACTICE:
"Self-administered, outpatient-based treatment for PSVT could contribute to reduced ED visits and cost and complexity of care," the study authors wrote. SOURCE:
The study was led by Sean Pokorney, MD, MBA, Duke University School of Medicine, Durham, North Carolina. It was published online on April 9, 2025, in JAMA Cardiology . LIMITATIONS:
The trials were not individually powered to assess differences in ED visit rates, and data were pooled to achieve statistical power. DISCLOSURES:
This study was funded by Milestone Pharmaceuticals. Several authors reported receiving personal fees from Milestone Pharmaceuticals or having other ties with various sources.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape Medical News © 2025 WebMD, LLC
Cite this: Edited by Gargi Mukherjee. Self-Administered Etripamil Cuts Emergency Department Visits for Paroxysma Supraventricular Tachycardia - Medscape - May 13, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) approved Doptelet® (avatrombopag) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. 1 The approval also includes a new formulation, Doptelet Sprinkle (avatrombopag) oral granules, for use in children ages one to less than six years. 1 'Doptelet represents a significant advancement in the treatment of children and adolescents with persistent or chronic ITP,' said Rachael Grace, MD, MMSc, Pediatric Hematologist and Director, Hematology Clinical Research at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead investigator of the AVA-PED-301 study. 'This therapy offers simple, flexible administration because it is oral, available as a tablet and now as a new pediatric sprinkle formulation and has no food restrictions. The approval of Doptelet for pediatric ITP offers families a new treatment option that can help address challenges in managing ITP in pediatric patients.' Doptelet Sprinkle is the approved dosage form for patients aged one to less than six years, while Doptelet tablet is the approved dosage form for patients aged six and up. 1 The pediatric approval is based on results from AVA-PED-301, a global, randomized, phase 3 study evaluating the efficacy, safety, and pharmacokinetics of Doptelet in the treatment of pediatric subjects with ITP. The study showed that 27.8% of Doptelet patients achieved the primary endpoint of durable platelet response* versus 0% of placebo patients in the absence of rescue medication (p=0.0077, 95% CI 15.8-39.7). Also, 81.5% of Doptelet patients achieved the alternative primary endpoint of platelet response** versus no patients in the placebo group (p=<0.0001, 95% CI 71.1-91.8). At Day 8, 55.6% of Doptelet patients (95% CI: 41.4%, 69.1%) had a platelet count ≥50×10^9/L in the absence of rescue therapy (p<0.0001) versus no placebo patients (95% CI: 0.0%, 16.1%). Doptelet was generally well-tolerated. In pediatric patients with persistent or chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.1 'Since its introduction in 2019, Doptelet has been a cornerstone therapy for chronic ITP in adults,' said Duane Barnes, President of Sobi North America. 'This approval not only reinforces our commitment to innovation but also allows us to expand the treatment experience for patients and their families by offering Doptelet in two formulations.' Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low numbers of platelets, leading to bruising and an increased risk of bleeding. It is estimated up to 100 people per million live with ITP. In children, ITP occurs in five out of 100,000 children per year and up to 25% of newly diagnosed pediatric ITP patients develop chronic ITP. Currently, no cure is available, and patients usually relapse after various treatments. Indications Doptelet is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Important Safety Information Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving Doptelet. In adult patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving Doptelet. Doptelet should not be administered to patients with chronic liver disease or immune thrombocytopenia in an attempt to normalize platelet counts. The most common adverse reactions in clinical trials were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain. To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-866-773-5274 or FDA at 1-800-FDA-1088 or Please see the full Prescribing Information for Doptelet. * A durable response consisted of patients achieving a platelet count >=50,000/uL for six of the last eight weeks in the 12-week core phase of the AVA-PED-301 study. ** Efficacy was also evaluated by platelet response, defined as the proportion of subjects achieving at least two consecutive platelet assessments ≥50×10^9/L in the core phase in the absence of rescue medication. About Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding, and represents a multi-faceted disease burden for children and adolescents. Bleeding can range from minor symptoms, such as bruising, to more severe findings such as intracranial hemorrhage. ITP can also have a significant impact on quality of life including severe fatigue and restrictions on physical activity due to risk of bleeding. About Doptelet® (avatrombopag) Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by the US Food & Drug Administration (FDA) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and by the European Medicines Agency (EMA) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. In June 2019, Doptelet was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and in 2021, Doptelet was approved by EMA for the treatment of primary chronic ITP in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). About Sobi North America As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi's vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at or at About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here. References 1. Doptelet Prescribing Information. Doptelet U.S. Product Information. Last updated: July 2025. Morrisville, NC: AkaRx, Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
4 days ago
- Business Wire
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners. NFL Biosciences obtained a €600,000 'Innovation Advance' repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate. This €1.2 million adds to the €3.0 million raised in the oversubscribed capital increase at the end of May 2025. The company also expects to secure additional non-dilutive funding and plans to benefit each year from the reimbursement of a portion of its R&D expenses through the Research Tax Credit. These funds are allocated to the continued development of NFL-101, its proprietary drug indicated for smoking cessation. The company is currently engaged in scientific advice procedures with European regulatory authorities and the FDA. The feedback expected at the end of the summer will enable the company to confirm its development strategy, notably in relation to manufacturing, preclinical and clinical aspects. 'We would like to sincerely thank Bpifrance for its support, as well as our banking partners Société Générale and Banque Populaire du Sud. We have recently secured €4.2 million to support our development, and we are confidently approaching the launch of Phase 3. We are also continuing to seek additional non-dilutive funding and remain focused on rigorously managing our structural costs,' commented Bruno Lafont, Chief Executive Officer of NFL Biosciences. About NFL Biosciences: NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on
Medscape
17-07-2025
- Medscape
10-Minute Test Exposes Antibiotic Resistance Threat
Current methods for assessing antibiotic resistance typically rely on bacterial cultures, a process that can take up to 2 days. Such delays can be critical in urgent clinical settings. To address this, researchers at France's National Institute for Research in Digital Science and Technology (Inria) are developing a rapid method that can deliver results within a few hours or even minutes. This new approach is based on the principle that antibiotic resistance results from mutations in the bacterial genome. In theory, sequencing can detect these changes; however, conventional sequencing methods are time-consuming. Karel Břinda, PhD, is a permanent Principal Investigator with the GenScale team at Inria Rennes, one of the regional research centers of Inria. He specializes in computational genomics and rapid diagnostic methods. The technique he developed compared bacterial DNA from patient samples with a reference database of genomes from bacteria known to be resistant or sensitive to antibiotics. Bacteria with similar DNA sequences are likely to exhibit similar resistance profiles. This method, known as Genomic Neighbor Typing, offers two key advantages: It does not require prior knowledge of the pathogen's complex biology, and it can generate predictions from minimal sequencing data, making it exceptionally fast. 'We've shown that once sequencing begins, we can predict resistance or susceptibility in about 10 minutes,' Břinda explained in an interview published by Inria. The technique uses a compact, portable nanopore sequencing device that is approximately the same size as a smartphone. 'With nanopores, you receive a continuous stream of data as soon as the device starts sequencing. Our method allows you to make a prediction almost immediately from this initial data, so the diagnosis is very fast,' he said. 'These devices also produce very long reads, which help identify the nearest genomic neighbors of the pathogen present in the patient's biological samples,' Břinda said. Although promising, this method has only been validated for Streptococcus pneumoniae and Neisseria gonorrhoeae . However, it is not yet applicable to all bacterial species or antibiotics, mainly because of gaps in existing genomic reference databases. To address this, Inria partnered with Rennes University Hospital, Rennes, France, to combine its computational tools with biological and clinical expertise. The hospital also houses a national collection of Enterococcus strains maintained by France's Reference Center for Antibiotic Resistance. 'In the long run, the key question revolves around building large and truly representative databases of bacterial strains,' said Břinda. 'Today, we work with databases of up to thousands of genomes. In the future, sequencing will become increasingly cheaper and more common. We will therefore have much larger databases. But we will then need new computational methods and new software.'
